Search Results - "Yamaura, Takumi"

Anaplastic Lymphoma Kinase-Tyrosine Kinase Inhibitor Treatment for Metastatic Non-small Cell Lung Cancer Throughout the Entire Gestation Period by Kato, Mari, Yamaura, Takumi, Mine, Hayato, Kin, Shogo, Suzuki, Hiroyuki

“…Non-small cell lung cancer (NSCLC) occasionally develops in younger, fertile patients. This early-onset NSCLC tends to have more oncogenic driver mutations…”
Get full text

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer by Ozaki, Yuki, Muto, Satoshi, Takagi, Hironori, Watanabe, Masayuki, Inoue, Takuya, Fukuhara, Mitsuro, Yamaura, Takumi, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Ohsugi, Jun, Hoshino, Mika, Shio, Yutaka, Tanaka, Daisuke, Nanamiya, Hideaki, Imai, Jun-ichi, Isogai, Takao, Watanabe, Shinya, Suzuki, Hiroyuki

“…Cancer treatment using immune checkpoint inhibitors is widely used, although biomarkers predictive of response are not well established. However, both the…”
Get full text

The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study by Fukuhara, Mitsuro, Muto, Satoshi, Inomata, Sho, Yamaguchi, Hikaru, Mine, Hayato, Takagi, Hironori, Ozaki, Yuki, Watanabe, Masayuki, Inoue, Takuya, Yamaura, Takumi, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Osugi, Jun, Hoshino, Mika, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki

“…Introduction The presence of tertiary lymphoid structure (TLS) in tumor tissues has been reported to be a factor associated with a good prognosis in several…”
Get full text

CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC by Muto, Satoshi, Inomata, Sho, Yamaguchi, Hikaru, Mine, Hayato, Takagi, Hironori, Ozaki, Yuki, Watanabe, Masayuki, Inoue, Takuya, Yamaura, Takumi, Fukuhara, Mitsuro, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Osugi, Jun, Hoshino, Mika, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki

“…Treatments containing ipilimumab have shown a good outcome in patients with non-small cell lung cancer (NSCLC) regardless of the PD-L1 tumor proportion score…”
Get full text

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer by Higuchi, Mitsunori, Owada, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Yamaura, Takumi, Fukuhara, Mitsuro, Hasegawa, Takeo, Suzuki, Hiroyuki

“…Nivolumab, an immune checkpoint inhibitor, is recently clinically applied to non-small cell lung cancer (NSCLC) treatment, and this causes T cell activation…”
Get full text

Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers by Muto, Satoshi, Enta, Akio, Maruya, Yoshiyuki, Inomata, Sho, Yamaguchi, Hikaru, Mine, Hayato, Takagi, Hironori, Ozaki, Yuki, Watanabe, Masayuki, Inoue, Takuya, Yamaura, Takumi, Fukuhara, Mitsuro, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Osugi, Jun, Hoshino, Mika, Higuchi, Mitsunori, Shio, Yutaka, Hamada, Kazuyuki, Suzuki, Hiroyuki

“…Lung cancer is the leading cause of cancer-related deaths worldwide. The standard of care for advanced non-small-cell lung cancer (NSCLC) without driver-gene…”
Get full text

Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature by Hasegawa, Takeo, Ozaki, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Fukuhara, Mitsuro, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki

“…Immune checkpoint inhibitor therapy has changed the standard drug therapy for relapsed or advanced non-small cell lung cancer; its efficacy is well-recognized…”
Get full text

Brief report on similar mutational changes in neurofibromatosis type 2 gene in minute pulmonary meningothelial-like nodule and meningioma of the central nervous system by Higuchi, Mitsunori, Watanabe, Masayuki, Inoue, Takuya, Yamaura, Takumi, Suzuki, Tomoko, Saito, Miwako, Niitsuma, Katsunao, Endo, Kotaro, Oshibe, Ikuro, Soeta, Nobutoshi, Saito, Takuro, Hojo, Hiroshi, Munakata, Mitsuru, Suzuki, Hiroyuki

“…Minute Pulmonary Meningothelial-like Nodules (MPMNs) are usually detected incidentally adjacent to lung cancer tissue. The pathogenesis is unknown. MPMNs…”
Get full text

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib by Matsumura, Yuki, Inomata, Sho, Yamaguchi, Hikaru, Mine, Hayato, Takagi, Hironori, Watanabe, Masayuki, Ozaki, Yuki, Yamaura, Takumi, Fukuhara, Mitsuro, Muto, Satoshi, Okabe, Naoyuki, Hasegawa, Takeo, Shio, Yutaka, Suzuki, Hiroyuki

“…Echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) rearrangements are found in ~ 5% of patients with non‐small cell lung…”
Get full text

Establishment of induced pluripotent stem cells from normal B cells and inducing AID expression in their differentiation into hematopoietic progenitor cells by Kawamura, Fumihiko, Inaki, Makoto, Katafuchi, Atsushi, Abe, Yu, Tsuyama, Naohiro, Kurosu, Yumiko, Yanagi, Aki, Higuchi, Mitsunori, Muto, Satoshi, Yamaura, Takumi, Suzuki, Hiroyuki, Noji, Hideyoshi, Suzuki, Shinichi, Yoshida, Mitsuaki A., Sasatani, Megumi, Kamiya, Kenji, Onodera, Masafumi, Sakai, Akira

“…B cell derived induced pluripotent stem cells (BiPSCs) were recently established from peripheral blood B cells by the simultaneous transfection of Yamanaka…”
Get full text

Genetic alterations in epidermal growth factor receptor‑tyrosine kinase inhibitor‑na ve non‑small cell lung carcinoma by Yamaura, Takumi, Muto, Satoshi, Mine, Hayato, Takagi, Hironori, Watanabe, Masayuki, Ozaki, Yuki, Inoue, Takuya, Fukuhara, Mitsuro, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Osugi, Jun, Hoshino, Mika, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki

Get full text

The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial by Inoue, Takuya, Takagi, Hironori, Owada, Yuki, Watanabe, Yuzuru, Yamaura, Takumi, Fukuhara, Mitsuro, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Osugi, Jun, Hoshino, Mika, Higuchi, Mitsunori, Shio, Yutaka, Yokouchi, Hiroshi, Kanazawa, Kenya, Ohbuchi, Katsuya, Fukushima, Takahisa, Munakata, Mitsuru, Suzuki, Hiroyuki

“…Cisplatin is a key drug in lung cancer therapy. However, cisplatin is also well known to induce gastrointestinal disorders, such as chemotherapy-induced nausea…”
Get full text

Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma by Okabe, Naoyuki, Matsumura, Yuki, Yonechi, Athushi, Hoshino, Mika, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki, Gotoh, Mitsukazu, Muto, Satoshi, Fukuhara, Mitsuro, Yamaura, Takumi, Watanabe, Yuzuru, Inoue, Takuya, Owada, Yuki, Kimura, Yuka, Osugi, Jun, Hasegawa, Takeo

“…Objective. The aim of this study was to investigate the prognostic value of MicroRNA-210 (miR-210) expression in patients with non-small-cell lung cancer…”
Get full text

Comparison of surgical outcomes after pneumonectomy and pulmonary function-preserving surgery for non-small cell lung cancer by Higuchi, Mitsunori, Takagi, Hironori, Ozaki, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Yamaura, Takumi, Fukuhara, Mitsuro, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Osugi, Jun, Hoshino, Mika, Shio, Yutaka, Suzuki, Hiroyuki

“…Background: According to previous reports, lobectomy with bronchoplasty or angioplasty is a more feasible surgery than pneumonectomy for central-type non-small…”
Get full text

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report by Osugi, Jun, Owada, Yuki, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Higuchi, Mitsunori, Suzuki, Hiroyuki, Gotoh, Mitsukazu

“…Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast,…”
Get full text

Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy by Yamaura, Takumi, Suzuki, Hiroyuki

Get more information

I. History of Immunotherapy and Cancer Vaccine for Lung Cancer by Suzuki, Hiroyuki, Takagi, Hironori, Owada, Yuki, Watanabe, Yuzuru, Inoue, Takuya, Fukuhara, Mitsuro, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Hasegawa, Takeo, Shio, Yutaka

Get more information

Exploring the Possibility of New Biomarkers of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer (NSCLC) by Owada, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Fukuhara, Mitsuro, Yamaura, Takumi, Muto, Satoshi, Matsumura, Yuki, Hasegawa, Takeo, Tanaka, Daisuke, Kanno, Ryo, Ito, Emi, Nanamiya, Hideaki, Imai, Junichi, Isogai, Takao, Watanabe, Shinya, Suzuki, Hiroyuki

“…Mutation burden in a tumor, presumably involving neo-antigens in the tumor tissue, is also thought to be one of the better predictors for the efficacy of…”
Get more information

Efficacy of exponentiation method with a convolutional neural network for classifying lung nodules on CT images by malignancy level by Usuzaki, Takuma, Takahashi, Kengo, Takagi, Hidenobu, Ishikuro, Mami, Obara, Taku, Yamaura, Takumi, Kamimoto, Masahiro, Majima, Kazuhiro

“…Objectives The aim of this study was to examine the performance of a convolutional neural network (CNN) combined with exponentiating each pixel value in…”
Get full text

Letter to the Editor: Comment on ‘‘Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer’’ by Usuzaki, Takuma, Takahashi, Kengo, Ishikuro, Mami, Obara, Taku, Yamaura, Takumi, Kamimoto, Masahiro, Majima, Kazuhiro

Get full text